Lefamulin

From WikiMD.org
Jump to navigation Jump to search

Lefamulin

Lefamulin (pronounced leh-fam-yoo-lin) is a pleuromutilin antibiotic drug used for the treatment of community-acquired bacterial pneumonia (CABP). It is marketed under the brand name Xenleta by Nabriva Therapeutics.

Etymology

The term "Lefamulin" is derived from the class of antibiotics it belongs to, known as pleuromutilin, and the suffix "-lin" which is common in many antibiotic names.

Usage

Lefamulin is used to treat adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms, including Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, and Mycoplasma pneumoniae.

Mechanism of Action

Lefamulin inhibits bacterial protein synthesis by binding to the peptidyl transferase center on the 50S subunit of the bacterial ribosome, thereby inhibiting the formation of peptide bonds during protein synthesis.

Side Effects

Common side effects of Lefamulin include nausea, diarrhea, vomiting, insomnia, and elevated liver enzymes. Serious side effects may include QT prolongation, Clostridium difficile-associated diarrhea, and hypersensitivity reactions.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski